Longboard Pharmaceuticals Inc (LBPH)
18.52
-1.43
(-7.17%)
USD |
NASDAQ |
Jun 14, 16:00
18.52
0.00 (0.00%)
Pre-Market: 20:00
Longboard Pharmaceuticals Cash from Financing (TTM): 295.24M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 295.24M |
| December 31, 2023 | 30.19M |
| September 30, 2023 | 26.74M |
| June 30, 2023 | 20.79M |
| March 31, 2023 | 20.92M |
| December 31, 2022 | -0.444M |
| September 30, 2022 | 0.00 |
| Date | Value |
|---|---|
| June 30, 2022 | -0.002M |
| March 31, 2022 | 3.17M |
| December 31, 2021 | 76.45M |
| September 30, 2021 | 133.01M |
| June 30, 2021 | 133.94M |
| March 31, 2021 | 132.00M |
| December 31, 2020 | 58.76M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-0.444M
Minimum
Dec 2022
295.24M
Maximum
Mar 2024
66.48M
Average
28.46M
Median
Cash from Financing (TTM) Benchmarks
| SIGA Technologies Inc | -36.02M |
| Mersana Therapeutics Inc | 78.96M |
| Pulmonx Corp | 1.544M |
| Maravai LifeSciences Holdings Inc | -42.44M |
| Caribou Biosciences Inc | 165.14M |